Last reviewed · How we verify
Numoquin (ethylhydrocupreine)
Numoquin (generic name: ethylhydrocupreine) is a ethylhydrocupreine drug. It is currently in unknown development.
Numoquin works by chelating copper ions, which are involved in various cellular processes.
Optochin is a derivative of quinine introduced in 1911 by Morgenroth and Levy to treat pneumococci infection. It is used in bacteriology to differentiate Streptococcus pneumoniae, which is optochin-sensitive, from other pneumococci.
At a glance
| Generic name | ethylhydrocupreine |
|---|---|
| Drug class | ethylhydrocupreine |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of Numoquin like a magnet that attracts and holds onto copper ions in the body. This can help reduce the amount of copper available to cause problems in cells. By chelating copper, Numoquin may help alleviate symptoms associated with copper overload or imbalance.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Numoquin CI brief — competitive landscape report
- Numoquin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Numoquin
What is Numoquin?
How does Numoquin work?
What is the generic name of Numoquin?
What drug class is Numoquin in?
What development phase is Numoquin in?
Related
- Drug class: All ethylhydrocupreine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing